Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains
Big Biotech’s Q2 Revenue Was 1% Above Consensus
Executive Summary
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
You may also be interested in...
Amgen Lays Out Plans For Rare Disease Portfolio Growth
Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase.
Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.